Canakinumab appears to be well-tolerated among pediatric patients with sickle cell anemia (SCA), according to research presented at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.
SCA is a heritable disease that predominantly affects people of African origin in the United States. It can lead to red blood cell membrane damage, which can cause long-term inflammation through the secretion of cytokines including interleukin 1-beta (IL-1B). Furthermore, intravascular inflammation (eg, increased serum C-reactive protein [CRP]) in SCA is predictive of morbidity and mortality.
For this study, researchers evaluated whether canakinumab — an IL-1B-targeting monoclonal antibody that blocks the cytokine’s downstream proinflammatory effects — is safe in patients with SCA and effective for reducing inflammation caused by IL-1B secretion.